Breckenridge Eyes First Kyprolis Generic With FDA Approval

US Firm Received ANDA Approval With Partner Natco

Towa’s US-based Breckenridge is aiming for exclusivity with its generic version of Amgen’s Kyprolis – developed with partner Natco Pharma – after obtaining one of the first approvals for several strengths of the treatment for relapsed or refractory multiple myeloma.

Entrance to FDA headquarters in Maryland
FDA approval follows a 2019 settlement deal • Source: Shutterstock

Breckenridge Pharmaceutical Inc. and partner Natco Pharma Limited are in pole position to be among the first US generic entrants for Amgen’s Kyprolis (carfilzomib) after Breckenridge received US Food and Drug Administration approval for its abbreviated new drug application.

The Indian firm noted that its partner had received final approval for 10mg and 60mg strengths of the product and...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Products

More from Generics Bulletin